PAK1 and chronic myelogenous leukemia, BCR-ABL1 positive: The inhibition of PAK1 signalling by IPA‐3 along with imatinib has been shown to enhance the apoptosis of leukaemic cells58 inferring its role as a therapeutic target in CML.